BOTOX(R) cosmetic (onabotulinumtoxinA) approved by the FDA
On Apr. 15, 2002, BOTOX(R) cosmetic (onabotulinumtoxinA), manufactured by Allergan, was approved by the Food and Drug Administration…
-
-
Scientists from NCI and FDA reported that patterns of proteins found in patients’ serum may reflect the presence of ovarian cancer
On Feb. 7, 2002, scientists from the National Cancer Institute (NCI) and the Food and Drug Administration (FDA)…
-
FDA approved Gleevec for gastrointestinal stromal tumors treatment
On Feb. 1, 2002, the U.S. Food and Drug Administration (FDA) approved the drug Gleevec, formerly known as…
-
Diagnostics | FDA | Medicine | Pharmaceutical | Therapeutics
The Best Pharmaceuticals for Children Act improved safety and efficacy of patented and off-patent medicines for children
In 2002, the U.S. Congress passed the Best Pharmaceuticals for Children Act that improved safety and efficacy of…
-
Biotechnology | FDA | Medicine | Therapeutics
The acquisition of Immunex by Amgen for $16 billion was announced
On Dec. 17, 2001, the acquisition of Immunex by Amgen was announced for $16 billion in stock and…
-
Biotechnology | Disease | FDA | Therapeutics
Genentech drug Cathflo Activase (alteplase) was approved
On Sept. 13, 2001, the Food and Drug Administration (FDA) announced it had approved Genentech’s request for it’s…
-
The FDA approved Gleevec, developed by OHSU, for treatment of chronic myeloid leukemia
On May 10, 2001, the U.S. Food and Drug Administration (FDA) approved Gleevec, the world’s first targeted cancer…
-
Corus Pharma was incorporated
On Jan. 12, 2001, Corus Pharma was incorporated as a private venture-backed development stage biopharmaceutical company focused on…
-
SynCardia Systems was founded
In 2001, SynCardia Systems, a private company formed to commercialize the Jarvik 7 artificial heart, was founded by…
-
Pathogenesis was acquired by Chiron for $660 million
On Sept. 22, 2000, Pathogenesis was acquired by Emeryville, California-based Chiron for $660 million or $38.50 per share….
-
Disease | FDA | Oncology | U.S. Congress
The Supreme Court ruled the FDA does not have authority to regulate tobacco as a drug
On Mar. 21, 2000, the Supreme Court ruled 5 to 4 along ideological lines, that the U.S. Food…
-
Eli Lilly and Takeda Chemical Industries launched Actos, an oral antidiabetes agent
In 2000, Eli Lilly and Takeda Chemical launched Actos, an oral anti diabetes agent. In 2005, a PROactive…
-
Biotechnology | FDA | Oncology | Therapeutics
FDA approved Targretin to treat certain T-cell lymphomas
On Dec. 29, 1999, the U.S. Food and Drug Administration (FDA) approved Bexarotene (Targretin) to treat cutaneous T-cell…
-
Diphtheria and tetanus toxoids and acellular pertussis vaccine was licensed
On Dec. 9, 1999, the diphtheria and tetanus toxoids and acellular pertussis vaccine (Tripedia by Connaught) was licensed….
-
The FDA approved LASIK corrective eye surgery
On Nov. 15, 1999, the FDA approved LASIK corrective eye surgery. LASIK stands for Laser-Assisted In Situ Keratomileusis…
-
Wyeth Lederle Vaccines voluntarily withdrew Rotashield from the market
On Oct. 15, 1999, Wyeth-Lederle Vaccines announced that it was withdrawing the Rotashield vaccine from the market and…
-
FDA approved a 2-dose schedule of hepatitis B vaccination for adolescents
On Aug. 27, 1999, Merck, West Point, Pennsylvania) received approval from the Food and Drug Administration (FDA) of…
-
Eli Lilly and Company’s Effient approved by the FDA for the reduction of thrombotic cardiovascular events
On Jul. 11, 1999, Daiichi Sankyo and Eli Lilly announced the U.S. Food and Drug Administration (FDA) had…
-
ZymoGenetics was instrumental in development of new hemophilia drug
On Mar. 27, 1999, Novo Nordisk, the ZymoGenetics parent company, announced approval of NovoSeven by the Food and…
-
Rule publication defined dietary supplements labeling
On Mar. 23, 1999, the Food and Drug Administration (FDA) announced a rule publication that defined dietary supplements…
-
The Hybrid Capture II human papillomavirus (HPV) DNA test was approved by the FDA
On Mar. 17, 1999, the Hybrid Capture II human papillomavirus (HPV) DNA test was approved by the U.S….
-
The FDA mandated OTC drugs labels contain information in a standardized, consumer-friendly format
On Mar. 17, 1999, the Food and Drug Administration (FDA) published a regulation mandating that labels of all…
-
Jane E. Henney, MD, becomes the first woman Commissioner of Food and Drugs
On Jan. 17, 1999, Jane E. Henney, M.D., appointed by President Bill Clinton, became the first woman to…
-
Biotechnology | CDC | FDA | Infectious Disease | Vaccine
ACIP recommended DTaP vaccines for all five doses in the vaccination schedule
On Jan. 15. 1999, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices…
-
Biotechnology | Diagnostics | Disease | FDA | HIV | Therapeutics
Western Blot positive HIV tests done since Jan 1, 1999 became reportable by Texas State Law
On Jan. 1, 1999, HIV infection in adults (clients 13 years of age or older) became reportable by…
-
Biotechnology | Diagnostics | Disease | FDA | Therapeutics | U.S. Congress
FDA promulgated the Pediatric Rule
On Dec. 2, 1998, the Pediatric Rule was implemented that required drug manufacturers to study the efficacy and…
-
Biotechnology | Chemistry | Diagnostics | Disease | FDA | Oncology | Therapeutics | Women's Health
The FDA approved the monoclonal antibody Herceptin (Trastuzumab) for treatment of metastatic breast cancer
On Sept. 25, 1998, the U.S. Food and Drug Administration (FDA) approved the monoclonal antibody Herceptin (Trastuzumab) for…
-
Rotavirus vaccine, live, oral, tetravalent was licensed
On Aug. 31, 1998, Rotashield (Wyeth Laboratories, Marietta, Pennsylvania) was licensed by the U.S. Food and Drug Administration…
-
Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed (Certiva by North American Vaccine) was licensed
On Jul. 29, 1998, the Food and Drug Administration (FDA) licensed North American Vaccine, (Beltsville, Maryland) to distribute…
-
Biotechnology | FDA | Oncology | Therapeutics
The FDA approved Genentech drug Xeloda (capecitabine)
On April 30, 1998, the U.S. Food and Drug Administration (FDA) approved the Genentech’s drug Xeloda (capecitabine) for…
